Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial

SJ. Woo, M. Veith, J. Hamouz, J. Ernest, D. Zalewski, J. Studnicka, A. Vajas, A. Papp, V. Gabor, J. Luu, V. Matuskova, YH. Yoon, T. Pregun, T. Kim, D. Shin, NM. Bressler

. 2021 ; 139 (1) : 68-76. [pub] 20210101

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, hodnocení ekvivalence, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019570

Importance: Neovascular age-related macular degeneration is the leading cause of blindness in individuals 50 years or older. The availability of a ranibizumab biosimilar product (SB11) may facilitate access to an effective alternative to this treatment. Objective: To demonstrate equivalence of efficacy, similar safety, and similar immunogenicity of SB11 compared with the reference ranibizumab. Design, Setting, and Participants: This randomized, double-masked, parallel-group phase 3 equivalence study was conducted in 75 centers in 9 countries from March 14, 2018, to December 9, 2019, among 705 participants 50 years or older with neovascular age-related macular degeneration with active subfoveal choroidal neovascularization lesions. Analysis was performed on an intent-to-treat basis. Interventions: Intravitreous injection of SB11 or ranibizumab, 0.5 mg, every 4 weeks through week 48. Main Outcomes and Measures: Preplanned interim analysis after all participants completed the week 24 assessment of primary efficacy end points at week 8 for change from baseline in best-corrected visual acuity (BCVA) and week 4 for central subfield thickness (CST), with predefined equivalence margins for adjusted treatment differences of -3 letters to 3 letters for BCVA and -36 μm to 36 μm for CST. Results: Baseline and disease characteristics among 705 randomized participants (403 women [57.2%]; mean [SD] age, 74.1 [8.5] years) were comparable between treatment groups (SB11, 351; ranibizumab, 354). Least-squares mean (SE) changes in BCVA from baseline at week 8 were 6.2 (0.5) letters in the SB11 group vs 7.0 (0.5) letters in the ranibizumab group, with an adjusted treatment difference of -0.8 letter (90% CI, -1.8 to 0.2 letters). Least-squares mean (SE) changes in CST from baseline at week 4 were -108 (5) μm in the SB11 group vs -100 (5) μm in the ranibizumab group, with an adjusted treatment difference of -8 μm (95% CI, -19 to 3 μm). Incidences of treatment-emergent adverse events (231 of 350 [66.0%] vs 237 of 354 [66.9%]), including serious treatment-emergent adverse events (44 of 350 [12.6%] vs 44 of 354 [12.4%]) and treatment-emergent adverse events leading to study drug discontinuation (8 of 350 [2.3%] vs 5 of 354 [1.4%]), were similar in the SB11 and ranibizumab groups. Immunogenicity was low, with a cumulative incidence of antidrug antibodies up to week 24 of 3.0% (10 of 330) in the SB11 group and 3.1% (10 of 327) in the ranibizumab group. Conclusions and Relevance: These findings of equivalent efficacy and similar safety and immunogenicity profiles compared with ranibizumab support the use of SB11 for patients with neovascular age-related macular degeneration. Trial Registration: ClinicalTrials.gov Identifier: NCT03150589.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019570
003      
CZ-PrNML
005      
20210830101150.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1001/jamaophthalmol.2020.5053 $2 doi
035    __
$a (PubMed)33211076
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Woo, Se Joon $u Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
245    10
$a Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial / $c SJ. Woo, M. Veith, J. Hamouz, J. Ernest, D. Zalewski, J. Studnicka, A. Vajas, A. Papp, V. Gabor, J. Luu, V. Matuskova, YH. Yoon, T. Pregun, T. Kim, D. Shin, NM. Bressler
520    9_
$a Importance: Neovascular age-related macular degeneration is the leading cause of blindness in individuals 50 years or older. The availability of a ranibizumab biosimilar product (SB11) may facilitate access to an effective alternative to this treatment. Objective: To demonstrate equivalence of efficacy, similar safety, and similar immunogenicity of SB11 compared with the reference ranibizumab. Design, Setting, and Participants: This randomized, double-masked, parallel-group phase 3 equivalence study was conducted in 75 centers in 9 countries from March 14, 2018, to December 9, 2019, among 705 participants 50 years or older with neovascular age-related macular degeneration with active subfoveal choroidal neovascularization lesions. Analysis was performed on an intent-to-treat basis. Interventions: Intravitreous injection of SB11 or ranibizumab, 0.5 mg, every 4 weeks through week 48. Main Outcomes and Measures: Preplanned interim analysis after all participants completed the week 24 assessment of primary efficacy end points at week 8 for change from baseline in best-corrected visual acuity (BCVA) and week 4 for central subfield thickness (CST), with predefined equivalence margins for adjusted treatment differences of -3 letters to 3 letters for BCVA and -36 μm to 36 μm for CST. Results: Baseline and disease characteristics among 705 randomized participants (403 women [57.2%]; mean [SD] age, 74.1 [8.5] years) were comparable between treatment groups (SB11, 351; ranibizumab, 354). Least-squares mean (SE) changes in BCVA from baseline at week 8 were 6.2 (0.5) letters in the SB11 group vs 7.0 (0.5) letters in the ranibizumab group, with an adjusted treatment difference of -0.8 letter (90% CI, -1.8 to 0.2 letters). Least-squares mean (SE) changes in CST from baseline at week 4 were -108 (5) μm in the SB11 group vs -100 (5) μm in the ranibizumab group, with an adjusted treatment difference of -8 μm (95% CI, -19 to 3 μm). Incidences of treatment-emergent adverse events (231 of 350 [66.0%] vs 237 of 354 [66.9%]), including serious treatment-emergent adverse events (44 of 350 [12.6%] vs 44 of 354 [12.4%]) and treatment-emergent adverse events leading to study drug discontinuation (8 of 350 [2.3%] vs 5 of 354 [1.4%]), were similar in the SB11 and ranibizumab groups. Immunogenicity was low, with a cumulative incidence of antidrug antibodies up to week 24 of 3.0% (10 of 330) in the SB11 group and 3.1% (10 of 327) in the ranibizumab group. Conclusions and Relevance: These findings of equivalent efficacy and similar safety and immunogenicity profiles compared with ranibizumab support the use of SB11 for patients with neovascular age-related macular degeneration. Trial Registration: ClinicalTrials.gov Identifier: NCT03150589.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a inhibitory angiogeneze $x škodlivé účinky $x farmakokinetika $x terapeutické užití $7 D020533
650    _2
$a biosimilární léčivé přípravky $x škodlivé účinky $x farmakokinetika $x terapeutické užití $7 D059451
650    _2
$a neovaskularizace choroidey $x diagnóza $x farmakoterapie $x patofyziologie $7 D020256
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a injekce intravitreální $7 D058449
650    _2
$a makulární degenerace $x diagnóza $x farmakoterapie $x patofyziologie $7 D008268
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a ranibizumab $x škodlivé účinky $x farmakokinetika $x terapeutické užití $7 D000069579
650    _2
$a obnova funkce $7 D020127
650    _2
$a terapeutická ekvivalence $7 D013810
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vaskulární endoteliální růstový faktor A $x antagonisté a inhibitory $7 D042461
650    _2
$a zrak $x účinky léků $7 D014785
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a hodnocení ekvivalence $7 D000073843
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Veith, Miroslav $u Department of Ophthalmology, Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $u Department of Ophthalmology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Hamouz, Jan $u Department of Ophthalmology, Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $u Department of Ophthalmology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Ernest, Jan $u Department of Ophthalmology, Central Military Hospital, Prague, Czech Republic
700    1_
$a Zalewski, Dominik $u Diagnostic and Microsurgery Center of the Eye LENS, Olsztyn, Poland
700    1_
$a Studnicka, Jan $u Department of Ophthalmology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Prague, Czech Republic $u Department of Ophthalmology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Vajas, Attila $u Department of Ophthalmology, University of Debrecen, Debrecen, Hungary
700    1_
$a Papp, Andras $u Department of Ophthalmology, Semmelweis University, Budapest, Hungary
700    1_
$a Gabor, Vogt $u Department of Ophthalmology, Medical Centre, Hungarian Defence Forces, Budapest, Hungary
700    1_
$a Luu, James $u Retina Consultants of Southern Colorado, Colorado Springs
700    1_
$a Matuskova, Veronika $u Department of Ophthalmology, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine Masaryk University, Brno, Czech Republic
700    1_
$a Yoon, Young Hee $u Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
700    1_
$a Pregun, Tamás $u Department of Ophthalmology, Bajcsy-Zsilinszky Hospital, Budapest, Hungary
700    1_
$a Kim, Taehyung $u Medical Team, Samsung Bioepis, Incheon, Korea
700    1_
$a Shin, Donghoon $u Medical Team, Samsung Bioepis, Incheon, Korea
700    1_
$a Bressler, Neil M $u Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland $u Editor, JAMA Ophthalmology
773    0_
$w MED00180370 $t JAMA ophthalmology $x 2168-6173 $g Roč. 139, č. 1 (2021), s. 68-76
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33211076 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101150 $b ABA008
999    __
$a ok $b bmc $g 1690411 $s 1140016
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 139 $c 1 $d 68-76 $e 20210101 $i 2168-6173 $m JAMA Ophthalmology $n JAMA Ophthalmol $x MED00180370
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...